Anti-NMDAR Encephalitis in the Netherlands, Focusing on Late-Onset Patients and Antibody Test Accuracy.
Anna E M BastiaansenMarienke A A M de BruijnSabine L SchullerEugenia Martinez-HernandezJuliëtte BrennerManuela PaunovicYvette S CrijnenMaxim J H L MulderMarco W J SchreursEsther de GraaffPeter A E SmittRinze Frederik NeuteboomJuna M de VriesMaarten J TitulaerPublished in: Neurology(R) neuroimmunology & neuroinflammation (2021)
Anti-NMDAR encephalitis occurs at all ages and is less rare in the elderly patients than initially anticipated. In older patients, the clinical phenotype is less outspoken, has different tumor association, and a less favorable recovery. Detection of antibodies in CSF is the gold standard, and although the CBA has very good validity, it is not perfect. The clinical phenotype should be leading, and confirmation in a research laboratory is recommended, when in doubt.